作者:Mohamed Elsawy、Irina Tikhonova、Lorraine Martin、Brian Walker
DOI:10.2174/0929866522666150622101626
日期:2015.8.5
The peptidic nature of anti-IAPs N-terminus Smac-derived peptides precludes their utilization
as potential therapeutic anticancer agents. Recent advances in the development of novel Smacderived
peptidomimetics and non-peptidic molecules with improved anti-IAPs activity and resistance
to proteolytic cleavage have been reported and led to a number of candidates that are currently in
clinical trials including LCL-161, SM-406/AT-406, GDC-0512/GDC-0917, and birinapant. As an attempt
to improve the proteolytic stability of Smac peptides, we developed the Aza-peptide AzaAla-
Val-Pro-Phe-Tyr-NH2 (2). Unlike unmodified peptide Ala-Val-Pro-Phe-Tyr-NH2 (1), analogue (2) exhibited resistance
towards proteolytic cleavage by two aminopeptidases; LAP and DPP-IV, while retaining its IAP inhibitory activity. This
was due to the altered planar geometry of the P1 residue side chain. Our findings showed that using aza-isosteres of bioactive
peptide sequences imbue the residue with imperviousness to proteolysis; underscoring a potential approach for developing
a new generation of Smac-derived Aza-peptidomimetics.
抗 IAP N 末端 Smac 衍生肽的肽性质阻碍了它们的利用
作为潜在的治疗性抗癌药物。新型 Smacogenic 开发的最新进展
具有改善的抗 IAP 活性和耐药性的肽模拟物和非肽分子
已报道了蛋白水解裂解,并导致了目前正在研究的许多候选物
临床试验包括 LCL-161、SM-406/AT-406、GDC-0512/GDC-0917 和 birinapant。作为一种尝试
为了提高 Smac 肽的蛋白水解稳定性,我们开发了 Aza 肽 AzaAla-
Val-Pro-Phe-Tyr-NH2 (2)。与未修饰的肽 Ala-Val-Pro-Phe-Tyr-NH2 (1) 不同,类似物 (2) 表现出抗性
通过两种氨肽酶进行蛋白水解切割; LAP 和 DPP-IV,同时保留其 IAP 抑制活性。这
这是由于 P1 残基侧链的平面几何形状发生了改变。我们的研究结果表明,使用生物活性的氮杂电子等排体
肽序列使残基不被蛋白水解作用;强调了一种潜在的发展方法
新一代 Smac 衍生的 Aza 肽模拟物。